Physician profile
Carlos B Jorge
NPI 1013925486
$2,889.74
in general payments reported to CMS, 2019-2025
43 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $992 · 2020: $218 · 2021: $600 · 2022: $265 · 2023: $361 · 2024: $242 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $931.18 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $260.96 | 2019-2024 | Farxiga, Airsupra |
| Lilly USA, LLC | $232.90 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $143.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $109.19 | 2019-2023 | |
| Cleerly, INC. | $104.92 | 2024 | Cleerly Ischemia, Cleerly Labs |
| Abbvie INC. | $81.73 | 2019-2023 | |
| Bausch Health US, LLC | $79.03 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.05 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $59.26 | 2019 | |
| Antares Pharma, INC. | $59.08 | 2019 | |
| Merck Sharp & Dohme LLC | $53.46 | 2019-2021 | |
| Exact Sciences Corporation | $50.74 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $49.47 | 2019 | |
| Acella Pharmaceuticals, LLC | $49.05 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Jorge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.